Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy

Klinik und Poliklinik für Infektiologie, University Hospital Berne and University of Berne, Inselspital PKT2B, 3010 Bern, Switzerland.
Gut (Impact Factor: 13.32). 09/2010; 59(9):1252-8. DOI: 10.1136/gut.2009.205971
Source: PubMed

ABSTRACT Hepatitis C virus (HCV) infection is a major cause of morbidity in HIV infected individuals. Coinfection with HIV is associated with diminished HCV-specific immune responses and higher HCV RNA levels.
To investigate whether long-term combination antiretroviral therapy (cART) restores HCV-specific T cell responses and improves the control of HCV replication.
T cell responses were evaluated longitudinally in 80 HIV/HCV coinfected individuals by ex vivo interferon-gamma-ELISpot responses to HCV core peptides, that predominantly stimulate CD4(+) T cells. HCV RNA levels were assessed by real-time PCR in 114 individuals.
The proportion of individuals with detectable T cell responses to HCV core peptides was 19% before starting cART, 24% in the first year on cART and increased significantly to 45% and 49% after 33 and 70 months on cART (p=0.001). HCV-specific immune responses increased in individuals with chronic (+31%) and spontaneously cleared HCV infection (+30%). Median HCV RNA levels before starting cART were 6.5 log(10) IU/ml. During long-term cART, median HCV-RNA levels slightly decreased compared to pre-cART levels (-0.3 log10 IU/ml, p=0.02).
Successful cART is associated with increasing cellular immune responses to HCV core peptides and with a slight long-term decrease in HCV RNA levels. These findings are in line with the favourable clinical effects of cART on the natural history of hepatitis C and with the current recommendation to start cART earlier in HCV/HIV coinfected individuals.


Available from: Huldrych F Günthard, May 30, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Coinfection with HIV adversely impacts every stage of hepatitis C (HCV) infection. Liver damage in HCV infection results from host antiviral responses rather than direct viral pathogenesis. Despite depressed cellular immunity, coinfected patients show accelerated hepatic fibrosis compared with HCV monoinfected patients. This paradox is poorly understood. T-regulatory (Treg) cells (CD4+ and FOXP3+) are hypothesized to limit hepatic damage in HCV. Our hypothesis was that reduced frequency of hepatic Treg in HIV/HCV coinfection compared with HCV monoinfection may explain poorer outcomes. We quantified FOXP3+, CD4+, CD8+ and CD20+ cells in liver biopsies of 35 male subjects matched by age and ISHAK fibrosis score, 12 HIV monoinfected, 11 HCV monoinfected and 12 HIV/HCV coinfected. Cell counts were performed using indirect immunohistochemical staining and light microscopy. HIV/HCV coinfected subjects had fewer hepatic FOXP3+ (P = 0.031) and CD4+ cells (P = 0.001) than HCV monoinfected subjects. Coinfected subjects had more hepatic CD8+ cells compared with HCV monoinfected (P = 0.023), and a lower ratio of FOXP3+ to CD8+ cells (0.08 vs 0.27, P < 0.001). Multivariate analysis showed number of CD4+ cells controlled for differences in number of FOXP3+ cells. Fewer hepatic FOXP3+ and CD4+ cells in HIV/HCV coinfection compared with HCV monoinfection suggests lower Treg activity, driven by an overall loss of CD4+ cells. Higher number of CD8+ cells in HIV/HCV coinfection suggests higher cytotoxic activity. This may explain poorer outcomes in HIV/HCV coinfected patients and suggests a potential mechanism by which highly active antiretroviral therapy may benefit these patients.
    Journal of Viral Hepatitis 04/2014; 21(4). DOI:10.1111/jvh.12141 · 3.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) cause substantial mortality, especially in persons chronically infected with both viruses. HIV infection raises plasma HCV RNA levels and diminishes the response to exogenous alpha interferon (IFN). The degree to which antiretroviral therapy (ART) control of infection overcomes these HIV effects is unknown. Participants with HIV‐HCV coinfection were enrolled in a trial to measure HCV viral kinetics after IFN administration (ΔHCVIFN) twice: initially before (pre‐ART) and then after (post‐ART) HIV RNA suppression. Liver tissue was obtained 2‐4 hours before each IFN injection to measure interferon stimulated genes (ISGs). Following ART, the ΔHCVIFN at 72 hours (ΔHCVIFN,72) increased in 15/19 (78.9%) participants by a median (interquartile range [IQR]) of 0.11 log10 IU/mL (0.00‐0.40; P IFN,72 post‐ART were associated with decreased hepatic expression of several ISGs (r = −0.68; P = 0.001); a 2‐fold reduction in a four‐gene ISG signature predicted an increase in ΔHCVIFN,72 of 0.78 log10 IU/mL (95% confidence interval [CI] 0.36,1.20). Pre‐ and post‐ART ΔHCVIFN,72 were closely associated (r = 0.87; P ART): transient median increases of 0.28 log10 IU/mL were followed by eventual median decreases from baseline of 0.21 log10 IU/mL (P = 0.002). A bivariate model of HIV RNA control (P P ART. Conclusion: ART is associated with lower post‐IFN HCV RNA levels and that change is linked to reduced hepatic ISG expression. These data support recommendations to provide ART prior to IFN‐based treatment of HCV and may provide insights into the pathogenesis of HIV‐HCV coinfection. (Hepatology 2014;60:477–486)
    Hepatology 08/2014; 60(2). DOI:10.1002/hep.27158 · 11.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We investigated changes in biomarkers of liver disease in HIV/HCV- coinfected individuals during successful combination antiretroviral therapy (cART) compared to changes in biomarker levels during untreated HIV-infection and to HIV-monoinfected individuals. Non-invasive biomarkers of liver disease [hyaluronic acid (HYA), APRI, FIB-4 and cytokeratin-18 (CK-18)] were correlated with liver histology in 49 HIV/HCV-coinfected patients. Changes in biomarkers over time were then assessed longitudinally in HIV/HCV-coinfected patients during successful cART (n=58), during untreated HIV-infection (n=59), and in HIV-monoinfected individuals (n=17). The median follow-up time was 3.4 years on-cART. All analyses were before starting HCV treatment. Non-invasive biomarkers of liver disease correlated significantly with the histological METAVIR-stage (P<0.002 for all comparisons). The AUROC values for advanced fibrosis (≥F3-METAVIR) for HYA, APRI, FIB-4 and CK-18 were 0.86±0.05, 0.84±0.08, 0.80±0.09 and 0.81±0.07, respectively. HYA, APRI and CK-18 levels were higher in HIV/HCV-coinfected compared to HIV-monoinfected patients (P<0.01). In the first year on cART, APRI and FIB-4 scores decreased (-35% and -33%, P=0.1), mainly due to the reversion of HIV-induced thrombocytopenia, while HYA and CK-18 levels remained unchanged. During long-term cART, there were only small changes (<5%) in median biomarker levels. Median biomarker levels changed less than 3% during untreated HIV-infection. Three patients died from end-stage liver disease, and 10 from other causes. Biomarkers of liver disease highly correlated with fibrosis in HIV/HCV-coinfected individuals and did not change significantly during successful cART. These findings suggest a slower than expected liver disease progression in many HIV/HCV-coinfected individuals, at least during successful cART.
    Antiviral therapy 09/2013; 19(2). DOI:10.3851/IMP2686 · 3.14 Impact Factor